ASND — Ascendis Pharma A/S

Ascendis Pharma A/S Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: €248 million, including Yorvipath revenue of €187 million and Skytrofa revenue of €53 million.
• Full-Year 2025 Revenue: €720 million, with Yorvipath contributing €477 million and Skytrofa €206 million.
• Operating Profit: €10 million in Q4; total operating expenses for the year were €761 million.
• Operating Cash Flow: €73 million in Q4; €616 million in cash and cash equivalents at year-end, up from €560 million in 2024.
• Impact of Currency: Weaker US dollar negatively impacted revenues by approximately €36 million for the year.

2. Strategic Updates and Business Highlights

• Yorvipath Launch: Strong global launch with over 5,300 patients prescribed by nearly 2,400 healthcare providers in the US. The insurance approval rate is around 70%, with expectations for growth as more patients are initiated on treatment.
• Skytrofa Performance: Continued solid performance with a 7% market share in the US. Initiated Phase III trials for additional growth hormone indications.
• TransCon PTH: Approved in the US and EU for hypoparathyroidism, with ongoing development for a once-weekly formulation.
• Pipeline Expansion: Focus on expanding the label for existing products and developing new therapies, including a collaboration with Novo Nordisk for once-monthly TransCon semaglutide.

3. Forward Guidance and Outlook

• 2026 Expectations: Projected operating cash flow of approximately €500 million and aim for at least €5 billion in annual product revenue by 2030.
• Yorvipath Growth: Anticipated continued strong revenue growth in 2026 based on steady patient uptake, with seasonal revenue trends expected.
• Skytrofa and TransCon CNP: Expect revenue growth to track prescription increases, with TransCon CNP's US approval anticipated soon.

4. Bad News, Challenges, or Points of Concern

• Insurance Approval Rate: While the current approval rate for Yorvipath is satisfactory, reaching 100% is unlikely and may take time due to natural filtering of eligible patients.
• Competitive Pressures: Concerns regarding emerging competitors like encaleret and long-acting CNP products from BioMarin. Management expressed skepticism about the efficacy of encaleret as a treatment for hypoparathyroidism.
• Regulatory Risks: The upcoming PDUFA date for TransCon CNP and the need for ongoing successful regulatory interactions pose inherent risks.

5. Notable Q&A Insights

• Confidence in TransCon CNP Approval: Management expressed strong confidence in the upcoming approval, reiterating their positive outlook.
• Yorvipath Utilization: Broad uptake across prescribers is encouraging, with a mix of patient demographics being treated, primarily post-surgical patients.
• Commercial Strategy: Ascendis has built a robust infrastructure for global commercialization, leveraging existing frameworks to expedite the launch of new products.
• Long-Term Independence: The CEO emphasized the goal of maintaining independence as a profitable biotech, highlighting the company's financial strength and strategic positioning.

Overall, Ascendis Pharma demonstrated strong financial performance in 2025, with a clear strategic vision for growth and product development, despite facing competitive and regulatory challenges.